Advertisement

An Infectious Disease Specialist’s Viewpoint

  • Alan M. Sugar
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 96)

Abstract

Systemic mycoses, once thought to be rare, exotic diseases, are more frequently being recognized as agents of serious infections in a diverse and emergent group of patients. Opportunistic fungal infections represent a significant cause of morbidity and mortality in the immunocompromised patient (MeunierCCarpentier et al. 1981; Gold 1984; Meunier 1987; Cairns 1988). The more common fungi, Candida, Aspergillus, and Cryptococcus, are not, however, the only agents responsible for this surge in the prevalence of mycotic disease. The organisms responsible for the ‘endemic mycoses’, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, and Paracoccidioides brasiliensis, are infecting large numbers of immunologically normal individuals who live in, or who have visited, the endemic areas. H. capsulatum and Co. immitis also are being increasingly recognized as causing refractory and usually fatal disease in immunosuppressed patients, especially those with the acquired immunodeficiency syndrome (AIDS) (Deresinski and Stevens 1975; Bronnimann et al. 1987; Salzman et al. 1988; Johnson et al. 1986). In addition, other fungi (e.g., Fusarium, Penicillium, Trichosporon, see Table 1) once thought to be relatively avirulent have been shown to produce systemic invasive disease (Anaissie et al. 1988; Walling et al. 1987; Deng et al. 1988). Sporotrichosis, chromoblastomycosis, and eumycetoma represent invasive mycotic infections occurring in different parts of the world and with varying frequencies.

Keywords

Candida Species Invasive Aspergillosis Antimicrob Agent Acquire Immunodeficiency Syndrome Invasive Candidiasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anaissie E, Kantarjian H, Ro J, Hopfer R, Rolston K, Fainstein V, Bodey G (1988) The emerging role of Fusarium infections in patients with cancer. Medicine 67: 77–83PubMedCrossRefGoogle Scholar
  2. Arena FP, Perlin M, Brahman H, Weiser B, Armstrong D (1981) Fever, rash, and myalgias of disseminated candidiasis during antifungal therapy. Arch Intern Med 141: 1233PubMedCrossRefGoogle Scholar
  3. Arroyo J, Medoff G, Kobayashi GS (1977) Therapy of murine aspergillosis with amphotericin B in combination with rifampin or 5-fluorocytosine. Antimicrob Agents Chemother 11: 21–25PubMedGoogle Scholar
  4. Bailey JW, Sada E, Brass C, Bennett JE (1985) Diagnosis of systemic candidiasis by latex agglutination for serum antigen. J Clin Microbiol 21: 749–752PubMedGoogle Scholar
  5. Beaman L, Benjamani E, Pappagianis D (1983) Activation of macrophages by lymphokines: enhancement of phagosome-lysosome fusion and killing of Coccidioides immitis. Infect Immun 39: 1201–1207PubMedGoogle Scholar
  6. Bennett JE (1981) Treatment of cryptococcal, candidal, and coccidioidal meningitis. In: Remington JS, Swartz MN (eds) Current clinical topics in infectious diseases. McGraw-Hill, New York, pp 54–67Google Scholar
  7. Bennett JE (1987) Rapid diagnosis of candidiasis and aspergillosis. Rev Infect Dis 9: 398–402PubMedCrossRefGoogle Scholar
  8. Bennett JE, Dismukes WE, Duma RJ (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 301: 126–131PubMedCrossRefGoogle Scholar
  9. Bronnimann DA, Adam RD, Galgiani JN, Habib MP, Petersen EA, Porter B, Bloom JW (1987) Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med 106: 372–379PubMedGoogle Scholar
  10. Brummer E, Stevens DA (1987) Activation of pulmonary macrophages for fungicidal activity by gamma-interferon or lymphokines. Clin Exp Immunol 70: 520–528PubMedGoogle Scholar
  11. Brummer E, Morrison CJ, Stevens DA (1985) Recombinant and natural gamma- interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun 49: 724–730.PubMedGoogle Scholar
  12. Brummer E, Hanson LH, Restrepo A, Stevens DA (1988) In vivo and in vitro activation of pulmonary macrophages by IFN-gamma for enhanced killing of Paracoccidioides brasiliensis or Blastomyces dermatitidis. J Immunol 140: 2786–2789PubMedGoogle Scholar
  13. Burnie J (1987) Latex tests in the early diagnosis of systemic candidosis. Serodiag Immunother 1: 3–5CrossRefGoogle Scholar
  14. Cairns MR (1988) Fungal infections in the acquired immunodeficiency syndrome. J Electron Microscopy Techniques 8: 115–131CrossRefGoogle Scholar
  15. Calhoun DL, Roberts GD, Galgiani JN, Bennett JE, Feingold DS, Jorgensen J, Kobayashi GS, Shadomy S (1986) Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol 23: 298–301PubMedGoogle Scholar
  16. Deepe GS Jr, Taylor CL, Harris JE, Bullock WE (1986) Modulation of cellular immune responses in mice with disseminated histoplasmosis by recombinant interleukin-2. Infect Immun 53: 6–12.PubMedGoogle Scholar
  17. Deng Z, Ribas JL, Gibson DW, Connor DH (1988) Infections caused by Penicillium marneffei in China and Southeast Asia: review of eighteen published cases and report of four more Chinese cases. Rev Infect Dis 10: 640–652PubMedCrossRefGoogle Scholar
  18. De Repentigny L, Reiss E (1984) Current trends in immunodiagnosis of candidiasis and aspergillosis. Rev Infect Dis 6: 301–312PubMedCrossRefGoogle Scholar
  19. De Repentigny L, Marr LD, Keller JW, Carter AW, Kuykendall RJ, Kaufman L, Reiss E (1985) Comparison of enzyme immunoassay and gas-liquid chromatography for the rapid diagnosis of invasive candidiasis in cancer patients. J Clin Microbiol 21: 972–979PubMedGoogle Scholar
  20. Deresinski SC, Stevens DA (1975) Coccidioidomycosis in compromised hosts. Experience at Stanford University Hospital. Medicine 54: 377–395PubMedCrossRefGoogle Scholar
  21. Dick JD, Merz WG, Saral R (1980) Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 18: 158–163PubMedGoogle Scholar
  22. Dick JD, Rosengard BR, Merz WG, Stuart RK, Hutchins GM, Saral R (1985) Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med 102: 67–68PubMedGoogle Scholar
  23. Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Craven PC, Kaplowitz LG, Fisher JF, Gregg CR, Bowles CA, Shadomy S, Stamm AM, Diasio RB, Kaufman L, et al. (1987) Treatment of cryptocoecal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 317: 334–341PubMedCrossRefGoogle Scholar
  24. Drutz DJ (1986) Antigen detection in fungal infections. N Engl J Med 314: 115–117PubMedCrossRefGoogle Scholar
  25. Dupont B, Huber M, Kim SJ, Bennett JE (1987) Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis 155: 1–10PubMedCrossRefGoogle Scholar
  26. Edwards JE Jr (1985) Candida species. In: Mandell GL, Douglas RG, Bennett JE (eds) Principles and practice of infectious diseases. Wiley, New York, pp 1435–1447Google Scholar
  27. Edwards JE Jr, Morrison J, Henderson DK, Montgomerie JZ (1980) Combined effect of amphotericin B and rifampin on Candida species. Antimicrob Agents Chemother 17: 484–487PubMedGoogle Scholar
  28. Fromtling RA (1987) (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, BarcelonaGoogle Scholar
  29. Galgiani JN, Reiser J, Brass C, Espinel-Ingroff A, Gordon MA, Kerkering TM (1987) Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother 31: 1343–1347PubMedGoogle Scholar
  30. Goering P, Berlinger NT, Weisdorf DJ (1988) Aggressive combined modality treatment of progressive sinonasal fungal infections in immunocompromised patients. Am J Med 85: 619–622PubMedCrossRefGoogle Scholar
  31. Gold JWM (1984) Opportunistic fungal infections in patients with neoplastic disease. Am J Med 76: 458–463PubMedCrossRefGoogle Scholar
  32. Greenfield RA, Troutt, DL, Rickard RC, Altmiller DH (1988) Comparison of antibody, antigen, and metabolite assays in rat models of systemic and gastrointestinal candidiasis. J Clin Microbiol 26: 409–417PubMedGoogle Scholar
  33. Henderson DK, Edwards JE Jr, Montgomerie JZ (1981) Hematogenous Candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. J Infect Dis 143: 655–661PubMedCrossRefGoogle Scholar
  34. Iwata K, Vanden Bossche H (1986) In vitro and in vivo evaluation of antifungal agents. Elsevier, NYGoogle Scholar
  35. Johnson PC, Sarosi GA, Septimus EJ, Satterwhite TK (1986) Progressive disseminated histoplasmosis in patients with the acquired immune deficiency syndrome: a report of 12 cases and a literature review. Sem Respir Infect 1: 1–8Google Scholar
  36. Kahn FW, Jones JM (1986) Latex agglutination tests for detection of Candida antigens in sera of patients with invasive candidiasis. J Infect Dis 153: 579–585PubMedCrossRefGoogle Scholar
  37. Karp JE, Burch PA, Merz WG (1988) An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 85: 203–206PubMedCrossRefGoogle Scholar
  38. Khardori N, von Behren L, Chaudhary S, McConnachie P, Strano A, Tewari RP (1986) Cellular mediators of anti-histoplasma immunity: I. Protective immunity and cellular changes in spleens of mice immunized by sublethal infection with yeast-cells of Histoplasma capsulatum. Mykosen 29: 103–115PubMedGoogle Scholar
  39. Levy R, Segal E, Eylan E (1981) Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fractions. Infect Immun 31: 874–878PubMedGoogle Scholar
  40. Levy R, Segal E, Eylan E, Barr-Nea L (1983) Cell–mediated immunity following experimental vaccinations with Candida albicans ribosomes. Mycopathologia 83: 161–168PubMedCrossRefGoogle Scholar
  41. Lew MA, Beckett KM, Levin MS (1977) Antifungal activity of four tetracycline analogs in vitro: potentiation by amphotericin B. J Infect Dis 136: 263–270PubMedCrossRefGoogle Scholar
  42. Mason MM, Lasker BA, Riggsby WS (1987) Molecular probe for identification of medically important Candida species and Torulopsis glabrata. J Clin Microbiol 25: 563–566PubMedGoogle Scholar
  43. Matthews R, Burnie J (1988) Diagnosis of systemic candidiasis by an enzyme-linked dot immunobinding assay for a circulating immunodominant 47-kilodalton antigen. J Clin Microbiol 26: 459–463PubMedGoogle Scholar
  44. Matthews RC, Burnie JP, Tabaqchali S (1984) Immunoblot analysis of the serological response in systemic candidosis. Lancet ii: 1415–1418Google Scholar
  45. McManus EJ, Jones JM (1985) Detection of a Trichosporon beigelii antigen cross- reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 21: 681–685PubMedGoogle Scholar
  46. Medoff G, Kobayashi GS (1980) Strategies in the treatment of systemic fungal infections. N Engl J Med 302: 145–155PubMedCrossRefGoogle Scholar
  47. Meunier F (1987) Prevention of mycoses in immunocompromised patients. Rev Infect Dis 9: 408–416PubMedCrossRefGoogle Scholar
  48. Meunier-Carpentier F, Kiehn TE, Armstrong D (1981) Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med 71: 363–370PubMedCrossRefGoogle Scholar
  49. Olivo PD, McManus EJ, Riggsby WS, Jones JM (1987) Mitochondrial DNA polymorphism in Candida albicans. J Infect Dis 156: 214–215PubMedCrossRefGoogle Scholar
  50. Pappagianis D (1986) Evaluation of the protective efficacy of the killed Coccidioides immitis vaccine in man. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans (Abstr 784 )Google Scholar
  51. Polak A, Scholer HJ, Wall M (1982) Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy 28: 461–479PubMedCrossRefGoogle Scholar
  52. Powderly WG, Kobayashi GS, Herzig GP, Medoff G (1988) Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 84: 826–832PubMedCrossRefGoogle Scholar
  53. Sabetta JR, Miniter P, Andriole VT (1985) The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen. J Infect Dis 152: 946–953PubMedCrossRefGoogle Scholar
  54. Salzman SH, Smith RL, Aranda CP (1988) Histoplasmosis in patients at risk for the acquired immunodeficiency syndrome in a nonendemic setting. Chest 93: 916–921PubMedCrossRefGoogle Scholar
  55. Scherer S, Stevens DA (1987) Application of DNA typing methods to epidemiology and taxonomy of Candida species. J Clin Microbiol 25: 675–679PubMedGoogle Scholar
  56. Sharma D, Khardori N, Chaudhary S, von Behren L, McConnachie P, Tewari RP (1986) Cellular mediators of anti-histoplasma immunity: II. Protective immunity and delayed hypersensitivity in mice immunized by sublethal infection with yeast cells of Histoplasma capsulatum. Mykosen 29: 116–126PubMedGoogle Scholar
  57. Sugar AM, Levitz SM (1988) Treatment of cryptococcal meningitis. N Engl J Med 318: 381CrossRefGoogle Scholar
  58. Talbot GH, Weiner MH, Gerson SL, Provencher M, Hurwitz S (1987) Serodiagnosis of invasive aspergillosis in patients with hematologic malignancy: validation of the Aspergillus fumigatus antigen radioimmunoassay. J Infect Dis 155: 12–27PubMedCrossRefGoogle Scholar
  59. Walling DM, McGraw DJ, Merz WG, Karp JE, Hutchins GM (1987) Disseminated infection with Trichosporon beigelii. Rev Infect Dis 9: 1013–1019PubMedCrossRefGoogle Scholar
  60. Wu-Hsieh BA, Howard DH (1987) Inhibition of the intracellular growth of Histoplasma capsulatum by recombinant murine gamma interferon. Infect Immun 55: 1014–1016PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Alan M. Sugar

There are no affiliations available

Personalised recommendations